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ABSTRACT
Introduction: Multiple sclerosis (MS) is
considered an autoimmune disease with
inflammatory and neurodegenerative underlying
processes that affect the central nervous system.
The available disease-modifying therapies (DMTs)
approved to treat MS have only shown partial
benefit in controlling the disease progression,
primarily impeding its inflammatory component,
while the parenteral administration of most of
these therapies has shown to affect patient
compliance. Laquinimod is a promising new oral
drug recently evaluated in a third phase III clinical
trial that demonstrated beneficial effects in
delaying disease progression and preventing brain
atrophy, suggesting a potential neuroprotective
effect and a favorable safety profile.
Areas Covered: This is a comprehensive review
covering clinical efficacyand safety data obtained
from two phase III clinical trials, as well as the
presumed beneficial mechanism of action, of
laquinimod. This article also provides a short
overview of the oral DMTs recently approved for
the treatment of relapsing MS, as well as
challenges that still remain to be overcome to
fully control the relentless course of MS.
Conclusion: Laquinimod has been shown to
have a novel immunomodulatory and potential
neuroprotective mechanism of action as
suggested from animal models and in vitro
experimental data. Phase III clinical trials
ALLEGRO (Clinicaltrials.gov #NCT00509145)
and BRAVO (Clinicaltrials.gov #NCT00605215)
have demonstrated clinical efficacy and
tolerability, while the third phase III study is
currently evaluating the safety and efficacy of
laquinimod at a higher dosage. Emerging oral
treatments like laquinimod will provide new
options for patients to consider that can lead to
Electronic supplementary material The online
version of this article (doi:10.1007/s40120-014-0017-6)
contains supplementary material, which is available to
authorized users.
C. Kolb-Sobieraj (&)  S. Gupta  B. Weinstock-
Guttman (&)
Department of Neurology, School of Medicine and
Biomedical Sciences, State University of New York at





C. Kolb-Sobieraj  S. Gupta  B. Weinstock-Guttman
Baird MS Center, Jacobs Neurological Institute,
Buffalo General Medical Center, New York, USA
S. Gupta
e-mail: sahil.mamc@gmail.com
Neurol Ther (2014) 3:29–39
DOI 10.1007/s40120-014-0017-6
better patient adherence and improved
outcomes.
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INTRODUCTION
New oral disease-modifying therapies (DMTs) are
currently available for the treatment of relapsing
multiple sclerosis (MS). Laquinimod (quinolin-3-
carboxamide) is one of the new once-a-day oral
medications being studied as a potential treatment
option for relapsing remitting MS [1]. Laquinimod
is structurally similar to another compound,
roquinimex (linomide) which was also studied as
a potential treatment for MS [2]. Roquinimex was
found in early phase II and III trials to prevent
clinical relapses and magnetic resonance imaging
(MRI) activity in MS. However, the phase III trials
were halted due to unexpected serious adverse
events suchas pericarditis, serositis andmyocardial
infarction that were not detected during the phase
II trials [3, 4]. Following the failed clinical trial with
roquinimex, laquinimod was discovered by
Jonsson et al. [5] in a structure activity screening
program to find compounds with efficacy against
autoimmune disorders but lacking the side effects
of roquinimex. Chemical modifications involving
the quinolone ring and elongation of the amidic
methyl group were performed on the roquinimex
structure which led to the discovery of laquinimod
with the chemical structure N-ethyl-N-phenyl-5-
chloro-1, 2-dihydro-4-hydroxy-1-methyl-2-oxo-3-
quinoline-carboxamide. These modifications led
to a 20-fold increase in potency of laquinimod in
treating animal models of experimental
autoimmune encephalomyelitis (EAE) with a
relatively favorable safety profile [6].
MS is considered an autoimmune disease
with inflammatory and neurodegenerative
underlying processes that affect the central
nervous system (CNS). Auto-reactive T
lymphocytes, B cells and macrophages enter
the CNS causing myelin and axonal destruction
and further chronic microglial activation [7].
Axonal damage and microglial activation lead
to the irreversible and relentless clinical
progression in patients with MS [8]. Due to the
heterogeneous response to therapies between
patients, often with suboptimal efficacy, and
concern for side effects associated with current
DMTs, new therapies are sought to address these
concerns. In particular, patients with
progressive MS have a great unmet need for
effective interventions. Developing new
therapies such as laquinimod may help
address some of these deficiencies.
This review is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
NOVEL MECHANISM OF ACTION
Laquinimod has shown to exert beneficial effects
on many in vitro and in vivo models of MS. A
graphic synopsis of its potential mechanism of
action is represented in Fig. 1. Laquinimod was
found to influence the ratio of pro-inflammatory
versus anti-inflammatory cytokine production in
EAE rat models and peripheral blood
mononuclear cells from healthy volunteers [9].
Cytokine analysis of EAE-induced rats treated
with laquinimod revealed a decrease in pro-
inflammatory markers, tumor necrosis factor-a
and interleukin (IL)-12. Concurrently, an increase
in anti-inflammatory markers transforming
growth factor-b and IL-4 were noted in the same
laquinimod-treated EAE rats [9]. It was also found
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that laquinimod given preventatively blocked the
entry of inflammatory T cells into the CNS.
Preventative treatment with laquinimod also
delayed clinical presentation of EAE in a dose-
dependent manner [10]. A dose-dependent effect
of laquinimod on reducing another pro-
inflammatory cytokine, IL-17, was also seen in
another experiment involving EAE rats treated
with laquinimod versus placebo [11]. The same
team observed a decrease in IL-17 and other pro-
inflammatory markers, IL-3 and granulocyte
colony-stimulating factor in peripheral blood
mononuclear cells from healthy human controls
[9].
Laquinimod was also found to inhibit acute
EAE clinical symptoms when administered after
the mice developed clinical symptoms of
progressive paresis. Oral laquinimod was able
to suppress clinical signs of disease in doses of
1 mg/kg/day and higher [6]. Laquinimod, given
at the time of symptom onset in myelin
oligodendrocyte glycoprotein-induced EAE,
reduced the severity of the disease at the dose
of 25 mg/kg/day. This was considered the
therapeutic dose. In another experiment,
laquinimod was given preventively at the time
of disease induction at doses of 5 mg/kg or 25
mg/kg/day. It was found that laquinimod had a
dose-dependent effect on preventing clinical
disease presentation of EAE in EAE-induced
mice [11].
Laquinimod was found to act more like an
immune modulating drug, rather than an
immunosuppressive one. Laquinimod-treated
rats were able to mount a cellular and
humoral response, including humoral
Fig. 1 The ﬁgure illustrates the mechanism of action of laquinimod and its presumed site of action. IFN interferon, IL
interleukin, TNF tumor necrosis factor
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immunoglobulin (Ig)M and IgG against a
presented pathogen [12]. Laquinimod did not
affect the proliferation or survival of peripheral
blood mononuclear cells in healthy human
subjects exposed to different concentrations of
the drug [12]. The viability of cardiac allograft
tissue in the presence of laquinimod also
testifies to its lack of immunosuppressive effect
[9].
Oral laquinimod penetrates the CNS in
physiologic and inflammatory pathologic
conditions. When oral 14C-laquinimod was
administered to track its distribution to the
brain and spinal cord in EAE and healthy mice,
healthy rats showed a 7–8% laquinimod
distribution to the brain and spinal cord in
relation to the peripheral blood concentration
at 2 h post dose, while EAE rats revealed a 13%
distribution of laquinimod to the brain and
spinal cord in relation to the peripheral blood at
an hour post dose [9]. A parallel time to the
peak concentration of laquinimod in the
peripheral blood and the CNS was identified in
the EAE model [9].
Laquinimod is thought to play a role in
neuroprotection as evidenced by its influence
on brain-derived neurotrophic factor (BDNF)
levels. BDNF is a protein that is involved in
strengthening synapses and promoting growth
and differentiation of new neurons. It is also an
important factor in promoting survival of
neurons in the central and peripheral nervous
system [13]. As part of a phase II trial, patients
(N = 200) given laquinimod 0.6 mg/day versus
placebo had their serum BDNF levels checked at
baseline, at 3 months and then at 9 months. It
was found that the laquinimod patients had
significantly higher levels of serum BDNF by
month three compared to placebo (P\0.01)
[14].
Axonal protection was also seen in animal
models treated with laquinimod. In one
experiment, rats were treated preventively (the
day of EAE inoculation) with laquinimod to
measure the degree of axonal damage in a
model of optic neuritis [6]. Axonal damage
and loss were measured by the accumulation of
amyloid precursor protein antibodies at the
sites of axonal damage and by the number of
fiber counts within the optic nerve. It was
observed that the day of disease manifestation
was significantly delayed in the group which
received laquinimod in the dosage of 5 mg/kg
subcutaneously. However, the severity of
symptoms did not differ between the groups,
which leads us to believe that laquinimod
effectively delays disease onset autoimmune
optic neuritis [15]. Another study used
scanning electron microscopy to visualize
axonal damage in the spinal cords of EAE mice
treated preventively with laquinimod versus
placebo [6]. The spinal cords of the
laquinimod-treated rats showed less
demyelination, inflammation and axonal loss
compared to the controls [6].
CLINICAL STUDIES
WITH LAQUINIMOD
Various phase I trials were performed to assess
the safety and tolerability of laquinimod. Eight
phase I trials used laquinimod with doses
ranging from 0.1 to 2.4 mg/day and found it
to be well tolerated [16]. The doses of 0.1 and
0.3 mg/day were subsequently used in the phase
IItrials.
Two phase II trials and one phase IIb trial
extension have been conducted to evaluate the
efficacy, safety and tolerability of laquinimod
compared to placebo [17–19]. The phase II study
conducted by Polman et al. [17] was a 24-week,
multicenter, double blind and three-armed
randomized trial. The primary outcome
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measure was the cumulative number of active
lesions over the length of the study. Patients
(N = 209) were randomized into three groups:
Laquinimod 0.3 mg/day, laquinimod 0.1 mg/
day and placebo. The primary outcome was
defined as the mean cumulative number of
active MRI lesions. Patients had MRI scans at
baseline, weeks 4, 8 and 24, and 8 weeks post
discontinuation of therapy. The mean
cumulative number of active lesions decreased
by 44% in the group treated with 0.3 mg/day of
laquinimod when compared to placebo
(P = 0.0498) [17]. The safety and tolerability
profile were found to be good and the adverse
events were similar in the placebo versus the
treatment groups. The investigators observed a
small increase in the erythrocyte sedimentation
rate and abnormal liver function test in the
treatment group but it was clinically
insignificant and did not warrant treatment
discontinuation [17].
Another phase IIb trial (LAQ/5062;
Clinicaltrials.gov #NCT00349193) compared
two doses of laquinimod (0.3 and 0.6 mg/day)
with placebo over a period of 36 weeks [19].
Three hundred and eight patients with active
MS disease were randomized and assigned to
one of the three groups. The primary outcome
measure was the cumulative number of
gadolinium-enhancing lesions at weeks 24, 28,
32 and 36 (last 4 scans of the treatment period)
[19]. The investigators observed a 40.4%
reduction in cumulative number of
gadolinium-enhancing lesions and 44%
reduction in the cumulative number of new
T2 lesions for 0.6 mg/day laquinimod as
compared to placebo. Annualized relapse rate
(ARR) also decreased in the 0.6 mg/day
treatment group by 32% but did not reach
statistical significance. Surprisingly, the group
treated with 0.3 mg/day dose of laquinimod
showed no significant differences from the
placebo group [19]. This was unforeseen as the
results from Polman et al. [17] suggested
promising results from the 0.3 mg/day
laquinimod-treatment group. This difference
in findings was attributed to the increased
sensitivity of the triple dose gadolinium used
in the trial by Polman et al. [17] and was also
believed that the lower dose of laquinimod took
longer time to reach statistical significance [19].
After the completion of LAQ/5062 trial, 257
out of the 308 subjects were enrolled in a
double-blind extension study (LAQ/5063;
Clinicaltrials.gov #NCT00745615) for another
36 weeks [18]. The treatment arm subjects were
continued on the medication but the subjects
on placebo arm were switched to laquinimod
0.3 or 0.6 mg/day. Among the patients switched
from placebo group to the treatment group,
there was a 52% decrease (P = 0.0006) in the
mean number of gadolinium-enhancing lesions
between the start and the end of the extension
phase. The reduction was more significant in
subjects that switched to laquinimod 0.6 mg/
day (P\0.009) group in comparison to
laquinimod 0.3 mg/day group (P\0.03).
Subjects that continued on the treatment
group showed sustained benefit throughout
the extension [18]. The safety and tolerability
profile was good in both LAQ/5062 trial and its
extension. A few serious adverse events
occurred in the treatment group in LAQ/5062
trial which could potentially be attributed to
laquinimod. One case of Budd-Chiari syndrome
was found in the laquinimod (0.6 mg/day)
group. The patient was taken off of
laquinimod but was later found to be
heterozygous for Factor V Leiden mutation
[18]. Another patient in the laquinimod
(0.3 mg/day) group developed marked increase
in liver function tests. Once the drug was
discontinued, the liver function tests gradually
normalized. Herpetic infections appeared more
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frequently in the 0.3 mg/day treatment group
but the difference in overall infection rates did
not differ between the treatment and the
placebo group. Safety and tolerability
remained unchanged during the extension
study and no unexpected adverse events
emerged except for three patients who
discontinued laquinimod due to liver enzyme
elevations [18]. Several patients in the
treatment group developed arthralgia but
recovered without drug discontinuation.
Surprisingly, the adverse effects due to
roquinimex, like pleuritis, pericarditis and
myocardial infarction, were absent in the
patients treated with laquinimod in the
clinical trials.
Following the encouraging phase II results,
the sponsors designed the phase III trials with
laquinimod at 0.6 mg/day dosage. ALLEGRO
(Assessment of oral Laquinimod in preventing
progression in Multiple Sclerosis;
Clinicaltrials.gov #NCT00509145) was a
multicenter, randomized controlled phase III
trial in which 1,106 patients were randomly
assigned to placebo or laquinimod (0.6 mg/day)
in 1:1 ratio and followed up for 24 months [1].
The primary end point was the ARR at
24 months. Key secondary end points included
the total number of gadolinium-enhancing
lesions and new or enlarging T2-weighted
lesions on MRI. The reduction in ARR for the
treatment group, although reaching
significance, was modest as compared to the
placebo group (0.30 vs. 0.39, respectively;
P = 0.002). Gadolinium-enhancing lesions
(1.33 vs. 2.12, respectively; P\0.001) and the
new/enlarging T2 lesions on MRI (5.03 vs. 7.14,
respectively; P\0.001) were also decreased in
the treatment group as compared to the placebo
group. Laquinimod was found to be well
tolerated in that 11.1% of patients suffered
serious adverse events while on laquinimod as
compared to 9.5% of patients on placebo [1].
Most common adverse events seen more
frequently in laquinimod treatment as
compared to placebo were elevated liver
enzymes (30% vs. 17.7%, respectively),
headache (22.7% vs. 17.8%, respectively), back
pain (16.4% vs. 9.0%, respectively), arthralgia
(8.5% vs. 7.6%, respectively) and diarrhea (8.0%
vs. 6.1%). All cases of elevated liver enzymes
were reversible either with treatment
continuation or within 2 months of treatment
discontinuation. Urinary tract infection (7.3%
vs. 4.5%, respectively) and sinusitis (5.3% vs.
4.5%, respectively) occurred more in
laquinimod groups as compared to the placebo
groups but no opportunistic infections were
identified in either group [1].
BRAVO (Benefit-risk assessment of Avonex
and Laquinimod; Clinicaltrials.gov
#NCT00605215) was a second phase III clinical
trial aimed to assess the efficacy, safety and
tolerability of laquinimod in comparison to
interferon (IFN) and placebo [20]. More than
1,300 patients were randomized 1:1:1 to oral
laquinimod, IFN-b1A and placebo for
24 months. The primary endpoint was the ARR
which did not reach statistical significance, but
showed a trend to reduction with laquinimod
[Risk ratio (RR) = 0.823, 95% CI 0.664–1.020;
P = 0.075]. However, following an adjustment
for imbalance of baseline MRI disease activity
between groups, the analysis demonstrated that
laquinimod significantly reduced ARR
compared to placebo (0.29 vs. 0.37,
RR = 0.787, 95%CI = 0.637–0.972; P = 0.026),
reduction in risk of disability progression
(Hazard ratio = 0.665; P = 0.44) and brain
atrophy on MRI (27.5%; P\0.0001) [20].
Safety profile in BRAVO was found to be
similar to that of ALLEGRO. Following a
similar adjusted analysis, ARR was found to be
reduced in the IFNb group (0.27) compared to
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placebo (0.29; P = 0.002). Disability progression
was reduced in IFN as compared to placebo
(28.7%; P = 0.089) but no treatment effect of
IFN was observed on brain atrophy [20].
A third phase III trial, CONCERTO
(Clinicaltrials.gov #NCT01707992), is currently
ongoing and aims to evaluate two doses of
laquinimod (0.6 and 1.2 mg/day) in
approximately 1,800 patients for 24 months.
The primary outcome measure will be disability
progression measured by the Expanded
Disability Status Scale (EDSS) [21].
CURRENT TREATMENT
AND UNMET NEED
The number of DMTs available today for
treating relapsing MS increased significantly
during the past decade and is expected to
increase further [22]. Glatiramer acetate and
IFN are still the drugs currently used as first-line
treatment in most countries, including the USA
[23–25]. These drugs are administered
parenterally and have favorable long-term
safety profiles. However, less than half of
patients respond to first-line therapies and the
adherence is often limited because of their
parenteral use including injection site
reactions. Other DMTs, like natalizumab or the
Food and Drug Administration (FDA) approved
oral drugs, can be considered [26]. Fingolimod,
teriflunomide and dimethyl fumarate are the
oral treatments which have been approved for
the treatment of MS (Table 1) [1, 20, 27–35].
Many more oral drugs, including laquinimod,
are on the horizon and are in different phases of
their respective clinical trials.
Despite the significant advances in the field
of MS, some glaring unmet needs still remain.
One of the most important challenges yet to be
addressed is whether the current treatments
hold the potential for completely arresting the
MS disease process. With the advent of drugs
like natalizumab and alemtuzumab, this notion
has emerged, especially if administered early in
the course of the disease, but further research is
still required. The benefit seen with
natalizumab, despite its high efficacy on
controlling the inflammatory process, is
hampered by the risk of developing
progressive multifocal leukoencephalopathy, a
potentially fatal and devastating disease, while
alemtuzumab is associated with a high risk of
developing other autoimmune diseases [33].
Another challenge that will require further
investigation is the lack of specific biomarkers
that can help select the best therapy for the
individual patient. As new therapies with
different mechanisms of action become
available, the possibility of developing
personalized therapy based on disease severity
and patient characteristics is a challenging but
actively pursued process.
HOW IT WILL FIT
INTO THE CURRENT TREATMENT
REGIMENS?
The upcoming oral drugs not only provide
convenient options for treatment of MS but
also pose a plethora of new challenges. The
severity of the disease and the risk–benefit
profile of the drugs would be instrumental in
determining the treatment strategies for
individual patients and constructing a
personalized management plan.
Oral drugs provide a more convenient and
suitable option for patients and are likely to be
prescribed more regularly as soon as their long-
term safety profiles are determined. Laquinimod
features as an attractive option for treatment of
MS because of its very favorable safety profile
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and tolerability [1]. The beneficial effect
associated with the use of laquinimod on
preventing disability progression and brain
atrophy as seen from the clinical trials may be
an attractive option for patients with a milder
inflammatory disease course [36]. Due to its
higher disability reduction rates, laquinimod
can be an attractive option for patients with
higher EDSS scores [1]. The higher dose data
(1.2 mg/day), presently under investigation,
will be very important in defining the specific
group of patients that will best benefit from this
medication [21]. Laquinimod can be also
prescribed to patients who have discontinued






Results Key adverse events
Fingolimod FREEDOMS, 1,272
[28]
ARRfor 0.5 mg FIN and 1.25 mg FIN vs. PL (0.18 and 0.16 vs. 0.40, respectively; P\ 0.001)
Risk of disability progression for 0.5 mg FIN and 1.25 mg FIN vs. PL (HR 0.7 and 0.68,
respectively; P = 0.02)
Cardiovascular events like






ARR for 0.5 mg and 1.25 FIN vs. IFNb (0.16 and 0.20 vs. 0.33, respectively; P\ 0.001)
Reduced brain lesions on MRI for FIN vs. IFNb
No signiﬁcant difference seen in disability progression
Teriﬂunomide TEMSO, 1,088 [31] Decreased ARR in TER 7 mg and TER 14 mg vs. PL (31.2% and 31.5%; P\ 0.001)
Decreased proportion of patients with disability progression in 7 mg TER and 14 mg TER vs.PL
(21.7% and 20.2% vs. 27.3%, respectively)




TOWER, 1,169 [32] Decreased ARR in TER 7 mg vs.PL and TER 14 mg vs. PL (22.3%, P = 0.02 vs. 36.3 %,
P\ 0.0001, respectively)
Decreased disability progression in 14 mg TER vs. PL
TENERE, 324 [33] Preliminary results:
No statistical superiority of IFNb over TER on risk of treatment failure (48.6%, 37.8%, and
42.3% in 7 mg, 14 mg, and IFNb, respectively)
ARR not statistically different in 14 mg TER and IFNb group (0.259 vs. 0.216).ARR in 7 mg
TER(0.410) higher than IFNb (0.216)
Dimethyl
fumarate
DEFINE, 1,237 [34] Decrease in proportion of people with relapse in DMF 240 mg bid and tid vs. PL (27% and 26%
vs. 46%, respectively; P\ 0.001)
ARR decreased in DMF 240 mg bid and tid vs. PL (0.17 and 0.19 vs. 0.36, respectively;
P\ 0.001)
Decrease in percentage of patients with disease progression as compared to PL(16 % in DMF bid,
P = 0.005; 18 % in tid DMF P = 0.01; 27 % in PL group)




CONFIRM, 1,430 [35] ARR decreased for DMF 240 mg bid (0.22; P\ 0.001), DMF 240 mg tid (0.20; P\ 0.001),
GA (0.29; P = 0.01) and 0.40 for PL
Decrease in MRI based endpoints in DMF and GA patients vs. PL (P = 0.01)
No differences in disability progression between DMF or GA vs. PL
Laquinimod ALLEGRO, 1,106 [1] Lower ARR in LAQ vs. PL (0.3 vs. 0.39; P = 0.02)
Decrease in risk of disability progression in LAQ vs. PL (11.1% vs. 15.7%; P = 0.01)
Decrease in MRI endpoints (P\ 0.001)
Elevated liver enzymes
Infections
BRAVO, 1,331 [20] After adjusted analysis, reduced ARR in LAQ vs. PL (21.3%; P = 0.026)
Reduction in disability progression in LAQ vs. PL (33.5%;P = 0.044)
Reduction in brain volume loss in LAQ vs. PL (27.5%; P\ 0.0001)
Clinical trial acronyms: ALLEGRO, Placebo Controlled Trial of Oral Laquinimod for Multiple Sclerosis; BRAVO, Laquinimod Double Blind Placebo Controlled Study in
RRMS Patients With a Rater Blinded Reference Arm of Interferon b-1a; CONFIRM, Comparator and an Oral Fumarate in RRMS; DEFINE, Determination of the Efﬁcacy
and Safety of Oral Fumarate in RRMS; FREEDOMS, A placebo-controlled trial of oral Fingolimod in Relapsing Multiple Sclerosis; TEMSO, The Teriﬂunomide Multiple
Sclerosis Oral Trial; TENERE, A study comparing the effectiveness and safety of Teriﬂunomide and Interferon Beta-1a in Patients with Relapsing multiple sclerosis; TOWER,
Teriﬂunomide efﬁcacy and safety in patients with relapsing multiple sclerosis; TRANSFORMS, Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting
Multiple Sclerosis
ARR annualized relapse rate, AV atrioventricular, bid twice a day, DMF dimethyl fumarate, FIN ﬁngolimod, GA Glatirameracetate, HR Hazard ratio, IFN interferon, LAQ
laquinimod, MRI magnetic resonance imaging, PL placebo, TER teriﬂunomide, tid three times a day
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the use of the parenteral first-line agents due to
side effects [27].
A few shortcomings of laquinimod should
also be considered while prescribing the drug.
First, 30% of the patients treated with
laquinimod in the ALLEGRO clinical trial
suffered from elevated liver enzymes.
Therefore, continuous monitoring of liver
enzymes is advised while prescribing
laquinimod [1]. Second, although laquinimod
maybe a safer drug, it is less effective as
compared to the already approved oral DMTs
and, therefore, shall be considered as an add-on
therapy to other DMTs [37]. Further studies are
also required to establish the efficacy of
laquinimod in progressive forms of MS disease
like primary progressive MS and secondary
progressive MS.
CONCLUSION
Laquinimod is a new oral medication evaluated
for the treatment of relapsing MS patients
which appears to be a convenient and suitable
option for patients to consider. Its favorable
safety profile and tolerability differentiates it
from the other emerging therapies. Elevated
liver enzymes is the only concerning side effect
of laquinimod which has been observed. This
side effect has proved to be reversible within
2 months of treatment discontinuation [16, 18].
Laquinimod acts through a multipronged
immunomodulatory mechanism of action and
may also exert a neuroprotective effect on the
neurons. Histopathological analysis of the EAE
model shows that laquinimod acts via
decreasing the infiltration of CD4? cells and
macrophages into CNS and neuroprotection
through preventing axonal damage [9, 11].
This multifaceted effect makes it an attractive
treatment option. Clinical trials, like ALLEGRO
and BRAVO, have established laquinimod as a
safe DMT, but lesser effective than the already
FDA-approved DMTs [1, 18, 20]. Therefore,
laquinimod can be considered as an add-on
drug to other MS therapies. If the ongoing phase
III trials confirm its efficacy and safety,
laquinimod would be a welcome and a much-
needed addition to the therapeutic options for
treatment of patients with relapsing and
possibly progressive MS [21]. All in all, the
impending arrival of the new oral therapies will
welcome a paradigm shift in the treatment of
relapsing MS with convenient drug
administration, better patient compliance and
better outcome.
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